Rosas-Peralta M, Borrayo-Sánchez G, Madrid-Miller A, Ramírez-Arias E, Pérez-Rodrígueze G

Idioma: Español
Referencias bibliográficas: 173
Paginas: 636-663
Archivo PDF: 455.36 Kb.

RESUMEN

Los ensayos controlados aleatorios y los estudios observacionales prospectivos ofrecen los datos más confiables sobre la asociación entre la presión arterial y la cardiopatía coronaria (CC). Toda la evidencia indica que hay una fuerte asociación entre la presión arterial y la CC, que es continua a niveles menores a 115 mm Hg de presión sistólica. En general, de los 60 a los 69 años de edad, la presión arterial sistólica más baja en 10 mm Hg se asocia con riesgo menor de tener un evento de enfermedad coronaria. El tamaño y la forma de esta asociación son constantes en todas las regiones, para hombres y mujeres, y para eventos mortales como el infarto de miocardio y el accidente vascular cerebral. Los ensayos han demostrado que los beneficios de la reducción de la presión arterial con diferentes clases de fármacos (diuréticos, betabloqueantes, inhibidores de la ECA, antagonistas del calcio) son bastante similares, con una quinta parte de reducción en enfermedad coronaria. Los puntos importantes de esta revisión son: a) que los beneficios relativos a la baja de la presión arterial para la prevención de enfermedad coronaria parecen ser constantes en una gama de diferentes poblaciones; b) que es probable que se obtenga un beneficio considerable con la presión arterial baja, por debajo de umbrales de hipertensión «tradicional» (140/90 mm Hg), especialmente en aquellos con alto riesgo absoluto, y c) que iniciar, reducir con precaución (sobre todo en el adulto mayor) y mantener la reducción de la tolerancia máxima de la presión arterial es un problema más importante que la elección del agente inicial.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761-2788.

2. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45:142-161.

3. Chobanian AV, Bakris GI, Black HR, Cushman WC, Green LA, Izzo JL Jr et al; The National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42: 1206-1252.

4. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D’Agostino RB, Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002;287:1003-1010.

5. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, Levy D. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001;103:1245-1249.

6. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies [published correction appears in Lancet. 2002;361:1060]. Lancet. 2002;360:1903-1913.

7. National Heart, Lung, and Blood Institute. Morbidity and Mortality: 2012 Chartbook on Cardiovascular, Lung and Blood Diseases. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health; 2012.

8. Lackland DT, Roccella EJ, Deutsch AF, Fornage M, George MG, Howard G et al.; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Council on Functional Genomics and Translational Biology. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke. 2014;45:315-353.

9. Miura K, Daviglus ML, Dyer AR, Liu K, Garside DB, Stamler J, Greenland P. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med. 2001; 161:1501-1508.

10. Yusuf S. Preventing vascular events due to elevated blood pressure. Circulation. 2006;113:2166 -2168.

11. Lackland DT, Keil JE, Gazes PC, Hames CG, Tyroler HA. Outcomes of black and white hypertensive individuals after 30 years of follow-up. Clin Exp Hypertens. 1995;17:1091-1105.

12. Gazes PC, Lackland DT, Mountford WK, Gilbert GF, Harley RA. Comparison of cardiovascular risk factors for high brachial pulse pressure in blacks versus whites (Charleston Heart Study, Evans County Study, NHANES I and II Studies). Am J Cardiol. 2008;102:1514–1517.

13. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials: Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet. 2000;356:1955-1964.

14. Van Bemmel T, Gussekloo J, Westendorp RGJ, Blauw GJ. In a population based prospective study, no association between high blood pressure and mortality after age 85 years. J Hypertens. 2006;24: 287–292.

15. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-1898.

16. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342:145-153.

17. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE et al.; SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial: the SAVE Investigators. N Engl J Med. 1992;327:669-677.

18. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet. 2003;362:782-788.

19. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N et al.; Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685-1697.

20. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA et al.; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010:362: 1575-1585.

21. Kannel WB. Some lessons in cardiovascular epidemiology from Framingham. Am J Cardiol. 1976;37: 269-282.

22. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2013 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013; 3:5-14.

23. American Diabetes Association. Standards of medical care in diabetes: 2013. Diabetes Care. 2013;36 (suppl.1):S11-S66.

24. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002;106:3143-3421.

25. Criqui MH, McClelland RL, McDermott MM, Allison MA, Blumenthal RS, Aboyans V et al. The anklebrachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2010;56:1506-1512.

26. McDermott MM, Liu K, Criqui MH, Ruth K, Goff D, Saad MF et al. Ankle-brachial index and subclinical cardiac and carotid disease: The Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol. 2005;162:33-41.

27. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB Sr, Gibbons R et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA Guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S49-S53.

28. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC Guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology American/Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S76-S99.

29. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. 2013 AHA/ACC/TOS Guideline for the management of overweight and obesity in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(suppl 2): S102-S138.

30. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S1-S45.

31. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med. 2009;26: 142-148.

32. US Department of Health and Human Services. 2004 Surgeon General’s Report: The Health Conse quences of Smoking. Atlanta, GA; US Department of Health and Human Services PHS, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.

33. Goldenberg I, Jonas M, Tenenbaum A, Boyko V, Matetzky S, Shotan A et al.; Bezafibrate Infarction Prevention Study Group. Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease. Arch Intern Med. 2003;163:2301-2305.

34. US Department of Health and Human Services. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services PHS, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2006.

35. US Office of the Surgeon General. Reducing the Health Consequences of Smoking: 25 Years of Progress: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services PHS; 1989:89-8411.

36. Isles C, Brown JJ, Cumming AM, Lever AF, McAreavey D, Robertson JI et al. Excess smoking in malignant- phase hypertension. BMJ. 1979;1:579-581.

37. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE; Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142:233-239.

38. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999– 2008. JAMA. 2010;303:235-241.

39. Chiang BN, Perlman LV, Epstein FH. Overweight and hypertension: A review. Circulation. 1969;39: 403-421.

40. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523-1529.

41. Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162:1867-1872.

42. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76-79.

43. Kotchen TA. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens. 2010;23:1170-1178.

44. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al.; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25:1751-1762.

45. Sharma AM, Pischon T, Engeli S, Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens. 2001;19: 667-674.

46. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network metaanalysis. Lancet. 2007;369:201-207.

47. Frohlich ED. Clinical management of the obese hypertensive patient. Cardiol Rev. 2002;10:127-138.

48. Wenzel UO, Krebs C. Management of arterial hypertension in obese patients. Current Hypertens Rep. 2007;9:491-497.

49. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol. 2007;50:563-572.

50. Anderson JL, Halperin JL, Albert N, Bozkurt B, Brindis RG, Curtis LH et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127: 1425-1443.

51. Coffman JD. Vasodilator drugs for peripheral vascular disease. N Engl J Med. 1979;301:159-160.

52. Roberts DH, Tsao Y, McLoughlin GA, Breckenridge A. Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Lancet. 1987; 2:650-653.

53. Solomon SA, Ramsay LE, Yeo WW, Parnell L, Morris-Jones W. Beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. BMJ. 1991;303: 1100-1104.

54. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: A meta-analysis of randomized controlled trials. Arch Intern Med. 1991; 151:1769-1776.

55. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL et al. ACC/AHA 2005 Practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): Executive summary: A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Circulation. 2006;113:1474-1547.

56. US Renal Data System. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End- Stage Renal Disease. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009.

57. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New Engl J Med. 2004;351:1296-1305.

58. Khouri Y, Steigerwalt SP, Alsamara M, McCullough PA. What is the ideal blood pressure goal for patients with stage III or higher chronic kidney disease? Curr Cardiol Rep. 2011;13:492-501.

59. Karohi C, Raggi P. Approach to cardiovascular disease prevention in patients with chronic kidney disease. Curr Treat Options Cardiovasc Med. 2012;14: 391-413.

60. Acelajado MC, Calhoun DA, Oparil S. Pathogenesis of hypertension. In: Black H, Elliott W, eds. Hypertension: A Companion to Braunwald’s Heart Disease. 2nd ed. Philadelphia, PA: Elsevier Sanders; 2012:12-26.

61. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6:772-783.

62. Katagiri H, Yamada T, Oka Y. Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ Res. 2007;101:27-39.

63. Ding K, Kullo IJ. Genome-wide association studies for atherosclerotic vascular disease and its risk factors. Circ Cardiovasc Genet. 2009;2:63-72.

64. Abd El-Aziz TA, Hussein YM, Mohamed RH, Shalaby SM. Renin angiotensin system genes polymorphism in Egyptians with premature coronary artery disease. Gene. 2012;498:270-275.

65. Konopka A, Szperl M, Piotrowski W, Roszczynko M, Stępińska J. Influence of renin-angiotensin system gene polymorphisms on the risk of ST-segmentelevation myocardial infarction and association with coronary artery disease risk factors. Mol Diagn Ther. 2011;15:167-176.

66. Tanner RM, Lynch AL, Brophy VH, Eckfeldt JH, Davis BR, Ford CE et al. Pharmacogenetic associations of MMP9 and MMP12 variants with cardiovascular disease in patients with hypertension. PLoS One. 2011;6: e23609.

67. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ et al. Finding the missing heritability of complex diseases. Nature. 2009;461: 747-753.

68. Pimenta E, Calhoun DA, Oparil S. Cardiology. In: Crawford MH, DiMarco JP, Paulus WJ, eds. 3rd ed. Etiology and Pathogenesis of Systemic Hypertension. Philadelphia, PA: Elsevier; 2009:511-522.

69. Laurent S, Boutouyrie P. Recent advances in arterial stiffness and wave reflection in human hypertension. Hypertension. 2007;49:1202-1206.

70. Dao HH, Essalihi R, Bouvet C, Moreau P. Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. Cardiovasc Res. 2005;66: 307-317.

71. Franklin SS, Gustin W 4th, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D. Hemodynamic patterns of age-related changes in blood pressure: the Framingham Heart Study. Circulation. 1997;96: 308-315.

72. Pimenta E, Oparil S. Management of hypertension in the elderly. Nat Rev Cardiol. 2012;9:286-296.

73. O’Rourke MF, Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol. 2007;50:1-13.

74. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D et al.; European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588-2605.

75. Wallace SM, Yasmin, McEniery CM, Mäki-Petäjä KM, Booth AD, Cockroft JR, Wilkinson IB. Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction. Hypertension. 2007;50:228-233.

76. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol. 1994;24:1468-1474.

77. Stewart KJ, Sung J, Silber HA, Fleg JL, Kelemen MD, Turner KL et al. Exaggerated exercise blood pressure is related to impaired endothelial vasodilator function. Am. J. Hypertens. 2004;17:314-320.

78. Endtmann C, Ebrahimian T, Czech T, Arfa O, Laufs U, Fritz M et al. Angiotensin II impairs endothelial progenitor cell number and function in vitro and in vivo: implications for vascular regeneration. Hypertension. 2011;58:394-403.

79. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci. 2003;24: 471-478.

80. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation. 1997;95:473-478.

81. Daugherty A, Rateri DL, Lu H, Inagami T, Cassis LA. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to aterosclerosis through the AT1A receptor. Circulation. 2004;110: 3849-3857.

82. Singh BM, Mehta JL. Interactions between the renin- angiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease. Arch Intern Med. 2003;163:1296-1304.

83. Lemarié CA, Schiffrin EL. The angiotensin II type 2 receptor in cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2010;11:19-31.

84. Ali Q, Hussain T. AT2 receptor non-peptide agonist C21 promotes natriuresis in obese Zucker rats. Hypertens Res. 2012;35:654-660.

85. Elliott WJ, Ram CV. Calcium channel blockers. J Clin Hypertens (Greenwich). 2011;13:687-689.

86. Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. J Clin Hypertens (Greenwich). 2011;13:639-643.

87. Taylor AA, Siragy H, Nesbitt S. Angiotensin receptor blockers: pharmacology, efficacy and safety. J Clin Hypertens (Greenwich). 2011:13:677-686.

88. Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Mbewu A, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst. Rev. 2012;11:CD002003.

89. Bakris GL, Weir MR, Secic M, Campbell B, Weis- McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004;65:1991-2002.

90. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.

91. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP et al.; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.

92. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V et al.; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.

93. Effects of treatment on morbidity in hypertension, II: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213: 1143-1152.

94. MRC trial of treatment of mild hypertension: principal results: Medical Research Council Working Party. BMJ (Clin Res Ed). 1985;291:97-104.

95. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP): SHEP Cooperative Research Group. JAMA. 1991;265:3255-3264.

96. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.

97. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963-969.

98. Black HR, Davis B, Barzilay J, Nwachuku C, Baimbridge C, Marginean H et al.; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care. 2008;31:353-360.

99. Cushman WC, Davis BR, Pressel SL, Cutler JA, Einhorn PA, Ford CE et al.; ALLHAT Collaborative Research Group. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich). 2012;14:20-31.

100. Barzilay JI, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Black HR et al.; ALLHAT Collaborative Research Group. Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcomes. 2012;5:153-162.

101. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.

102. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.

103. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.

104. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358: 1033-1041.

105. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension. 2001;38:E28-E32.

106. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J et al.; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351: 2058-2068.

107. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al.; VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031.

108. Sica DA. The Valsartan Antihypertensive Long-Term Use Evaluation trial: a study in contrasts. Hypertension. 2006;48:362-363.

109. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial: Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752-760.

110. Telmisartan Randomised Assessment Study in ACE intolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin- receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174-1183.

111. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.

112. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al.; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348: 1309-1321.

113. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al.; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364: 11-21.

114. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT- PALA): A multicentre randomised controlled trial. Lancet. 2005;366:895-906.

115. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB et al.; CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289:2073-2082.

116. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH et al.; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA. 2003;290:2805-2816.

117. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO et al. Randomised trial of effects of calcium antagonists compared with diuretics and betablockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359-365.

118. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late onset congestive heart failure in postinfarction patients with early reduction in ejection fraction: the Adverse Experience Committee and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991;83:52-60.

119. McMurray JJ, Abraham WT, Dickstein K, Køber L, Massie BM, Krumb H. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail. 2012;14:341-343.

120. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev. 2009:CD004349.

121. Elliott WJ. What should be the blood pressure target for diabetics? Curr Opin Cardiol. 2011;26:308-313.

122. Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154:541-548.

123. Izzo JL Jr, Gradman AH. Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. Med Clin North Am. 2004;88:1257-1271.

124. Vasan RS, Larson MG, Leip EP, Evans JC, O’Donnell CJ, Kannel WB, Levy D. Impact of high normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345:1291-1297.

125. Hsia J, Margolis KL, Eaton CB, Wenger NK, Allison M, Wu L et al.; Women’s Health Initiative Investigators. Prehypertension and cardiovascular disease risk in the Women’s Health Initiative. Circulation. 2007;115:855-860.

126. Fukuhara M, Arima H, Ninomiya T, Hata J, Yonemoto K, Doi Y et al. Impact of lower range of prehypertension on cardiovascular events in a general population: the Hisayama Study. J Hypertens. 2012;30: 893-900.

127. Canty JM Jr. Coronary pressure-function and steady-state pressure-flow relations during autoregulation in the unanesthetized dog. Circ Res. 1988; 63:821-836.

128. Harrison DG, Florentine MS, Brooks LA, Cooper SM, Marcus ML. The effect of hypertension and left ventricular hypertrophy on the lower range of coronary autoregulation. Circulation. 1988;77:1108-1115.

129. Rouleau JR, Simard D, Blouin A, Kingma JG Jr. Angiotensin inhibition and coronary autoregulation in a canine model of LV hypertrophy. Basic Res Cardiol. 2002;97:384-391.

130. Hoffman JI. Heterogeneity of myocardial blood flow. Basic Res Cardiol. 1995;90:103-111.

131. Strauer BE. The concept of coronary flow reserve. J Cardiovasc Pharmacol. 1992;19(suppl 5):S67-S80.

132. Sipahi I, Tuzcu EM, Schoenhagen P, Wolski KE, Nicholls SJ, Balog C et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol. 2006;48:833-838.

133. Stewart IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet. 1979;1:861-865.

134. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;1:581-584.

135. Millar JA, Lever AF. Implications of pulse pressure as a predictor of cardiac risk in patients with hypertension. Hypertension. 2000;36:907-911.

136. Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension: is there a point beyond which pressure reduction is dangerous? JAMA. 1991;265:489-495.

137. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J et al. Blood pressure, stroke and coronary heart disease, part 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990; 335:765-774.

138. Denardo SJ, Messerli FH, Gaxiola E, Aranda JM Jr, Cooper-Dehoff RM, Handberg EM et al. Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]). Am J Cardiol. 2010;106:498-503.

139. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144:884-893.

140. Thune JJ, Signorovitch J, Kober L, Velasquez EJ, McMurray JJV, Califf RM et al. Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertension. 2008;51:48-54.

141. Denardo SJ, Anderson RD, Pepine CJ. Blood pressure targets after high-risk myocardial infarction; is it time to update the guidelines? Hypertension. 2008; 51:26-27.

142. Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, La Rosa JC; Treating to New Targets Steering Committee and Investigators. Jcurve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J. 2010;31:2897-2908.

143. Dorresteijn JA, van der Graaf Y, Spiering W, Grobbee DE, Bots ML, Visseren FLJ; Secondary Manifestations of Arterial Disease Study Group. Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-curve revisited. Hypertension. 2012;59:14-21.

144. Waller PC, Isles CG, Lever AF, Murray GD, McInnes GT. Does therapeutic reduction of diastolic blood pressure cause death from coronary heart disease? J Hum Hypertens. 1988;2:7-10.

145. Fletcher A, Beevers DG, Bulpitt CJ, Butler A, Coles EC, Hunt D et al. The relationship between a low treated blood pressure and IHD mortality: A report from the DHSS Hypertension Care Computing Project (DHCCP). J Hum Hypertens. 1988;2:11-15.

146. Samuelsson OG, Wilhelmsen LW, Pennert KM, Wedel H, Berglund GL. The J-shaped relationship between coronary heart disease and achieved blood pressure level in treated hypertension: further analyses of 12 years of follow-up of treated hypertensives in the Primary Prevention Trial in Gothenburg, Sweden. J Hypertens. 1990;8:547-555.

147. Madhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension. 1994;23:395-401.

148. Kannel WB, Wilson PW, Nam BH, D’Agostino RB, Li J. A likely explanation for the J-curve of blood pressure cardiovascular risk. Am J Cardiol. 2004;94: 380-384.

149. Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP; INDANA Project Steering Committee, Individual Data Analysis of Antihypertensive intervention. Jshaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individualpatient data. Ann Intern Med. 2002;136:438-448.

150. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D et al.; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT Study: a randomized controlled trial. JAMA. 2004;292:2217-2225.

151. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris MI, Cowie CC, Stern MS, Boyko EJ, Reiber GE, Bennett PH, eds. Diabetes in America. 2nd ed. Washington, DC: National Institutes of Health; 1995:429-448.

152. Nilsson PM. ACCORD and risk-factor control in type 2 diabetes. N Engl J Med. 2010;362:1628-1629.

153. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23 (suppl 2): B54-B64.

154. Lackland DT, Elkind MS, D’Agostino R, Dhamoon MS, Goff DC Jr, Higashida RT et al.; on behalf of the American Heart Association Stroke Council; Council on Epidemiology and Prevention; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research. Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43:1998-2027.

155. Ovbiagele B, Diener H-C, Yusuf S, Martin RH, Cotton D, Vinisko R et al.; PROFESS Investigators. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA. 2011;306:2137-2144.

156. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.

157. Psaty BM, Furburg CD, Kuller LH, Cushman M, Savage PJ, Levine D et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality. Arch Intern Med. 2001; 161:1183-1192.

158. Denardo SJ, Gong Y, Nichols WW, Messerli FH, Bavry AA, Cooper-DeHoff RM et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med. 2010;123:719-726.

159. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS et al.; ACCF Task Force. ACCF/AHA 2011 expert consensus document on Hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011;123: 2434-2506.

160. Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP; PROVE IT-TIMI 22 Trial Investigators. What is the optimal blood pressure in patients after acute coronary syndromes? Relationship of blood pressure and cardiovascular events in the Pravastatin or Atorvastatin Evaluation and Infection Therapy- Thrombolysis in Myocardial Infarction (PROVE ITTIMI) 22 trial. Circulation. 2010;122:2142-2151.

161. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61-68.

162. Banach M, Bhatia V, Feller MA, Mujib M, Desai RV, Ahmed MI et al. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol. 2011;107:1208-1214.

163. Mancia G, Schumacher H, Redon J, Verdecchia P, Scmieder R, Jennings G et al. Blood pressure tar gets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation. 2011;124:1727-1736.

164. Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J et al.; ONTARGET Investigators. Safety and efficacy of low blood pressures among patients with diabetes. Subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial. J Am Coll Cardiol. 2012;59:74-83.

165. Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC et al. Achievement and safety of a low blood pressure goal in chronic renal disease: the Modification of Diet in Renal Disease Study Group. Hypertension. 1997;29:641-650.

166. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-lordache B, Turturro M et al.; REIN-2 Study Group. Bloodpressure control for renoprotection in patients with nondiabetic chronic renal disease (REIN-2): Multicentre randomised controlled trial. Lancet. 2005;365:939-946.

167. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M et al.; Task Force Members. 2013 ESH/ ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31: 1281-1357.

168. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA et al.; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2011;124:2458-2473.

169. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP et al.; American College of Cardiology Foundation. 2012 ACCF/AHA/ACP/AATS/PCNA/ SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:3097-3137.

170. Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ et al. 2014 ACC/AHA/AATS/ PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014; 130:1749-1767.

171. Qaseem A, Fihn SD, Dallas P, Williams S, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Management of stable ischemic heart disease: summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/ American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. Ann Intern Med. 2012;157:735-743.

172. Rosendorff C. Calcium antagonists in the treatment of hypertension in patients with ischaemic heart disease. Expert Opin Pharmacother. 2003;4:1535-1541.

173. Mason RP. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: Review of the evidence. Atherosclerosis. 2002;165:191-199.